查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593895

肺癌治疗市场：按分子、疾病、癌症类型、治疗方法、分布划分 - 全球预测 2025-2030

Lung Cancer Therapeutics Market by Molecules (Biologics, Small Molecules), Disease (NSCLC, SCLC), Cancer Type, Therapy, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肺癌治疗市值为250.4亿美元，预计2024年将达271.2亿美元，复合年增长率为8.39%，到2030年将达到440.3亿美元。

肺癌治疗的范围包括治疗和控制肺癌的多种治疗方法，包括化疗、免疫治疗、标靶治疗和放射线治疗。这些治疗方法的需求源自于肺癌的全球负担，肺癌仍然是全世界癌症相关死亡的主要原因之一。应用范围广泛，包括针对特定基因突变的治疗方法、支持术前肿瘤缩小以及加速术后恢復。最终用途范围主要包括医院、肿瘤中心以及学术和研究机构。精准医学的进步极大地影响了市场成长，导致个人化治疗计划和对肿瘤基因组学的了解不断加深。新药和联合治疗的核准率不断提高，以及预期转向更有效、副作用更少的治疗方法，正在出现最新的潜在商机。此外，製药公司和研究机构之间的合作对于加速药物开发和市场进入至关重要。然而，治疗费用上涨、核准流程冗长、地区间治疗可近性差异等限制因素已成为主要挑战。临床试验、病患招募和监管挑战的复杂性也阻碍了市场的成长。目前，最佳创新领域是液态切片和伴同性诊断的开发，以更好地为患者匹配正确的治疗方法，以及透过遗传和分子研究寻找新标靶。该市场充满活力、竞争激烈，技术进步迅速，这表明需要持续的研发投资和策略伙伴关係关係。驾驭这一复杂环境的有效策略包括促进创新、透过定价策略最大限度地提高患者的可及性，以及保持敏捷性以快速适应不断发展的科学和监管发展。

主要市场统计
基准年[2023] 250.4亿美元
预测年份 [2024] 271.2亿美元
预测年份 [2030] 440.3亿美元
复合年增长率（%） 8.39%

市场动态：揭示快速发展的肺癌治疗市场的关键市场洞察

供需的动态交互作用正在改变肺癌治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球肺癌发生率不断上升
    • 增强加强健康管理意识
    • 政府不断加强肺癌治疗倡议
  • 市场限制因素
    • 学名药大量供应
    • 肺癌治疗患者的平均寿命缩短
  • 市场机会
    • 增加新治疗方法研究和开发的资金
    • 采用免疫疗法等先进治疗方法
  • 市场挑战
    • 放射线治疗和化疗副作用的风险

波特五力：开拓肺癌治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肺癌治疗市场的外部影响

外部宏观环境因素在塑造肺癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肺癌治疗市场的竞争格局

肺癌治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵肺癌治疗市场供应商的绩效评估

FPNV定位矩阵是评估肺癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了肺癌治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肺癌治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球肺癌发生率上升
      • 加强医疗照护的意识不断增强
      • 加强政府对肺癌治疗的努力
    • 抑制因素
      • 学名药供应充足
      • 接受肺癌治疗的患者平均寿命缩短
    • 机会
      • 增加新疗法研究和开发的资金
      • 引进免疫疗法等先进疗法
    • 任务
      • 放疗和化疗副作用的风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 按分子分類的肺癌治疗市场

  • 生物製药
  • 小分子

第七章肺癌治疗市场：依疾病分类

  • 非小细胞肺癌
  • SCLC

第八章以癌症类型分類的肺癌治疗市场

  • 肺类癌
  • 非小细胞肺癌
  • 小细胞肺癌

第九章肺癌治疗市场疗法

  • 化疗
  • 免疫疗法
    • Atezolizumab
    • Durvalumab
    • 纳武单抗
    • Pembrolizumab
  • 放射治疗
    • 外樑
    • 内樑
    • 系统性的
  • 标靶治疗
    • Bevacizumab
    • Dabrafenib/曲美替尼
    • Erlotinib
    • Osimertinib

第十章肺癌治疗市场经销商

  • 医院药房
  • 网路药房
  • 零售药房

第十一章美洲肺癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区肺癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲肺癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-437A5D08AE3F

The Lung Cancer Therapeutics Market was valued at USD 25.04 billion in 2023, expected to reach USD 27.12 billion in 2024, and is projected to grow at a CAGR of 8.39%, to USD 44.03 billion by 2030.

The scope of lung cancer therapeutics encompasses a broad range of interventions designed to treat and manage lung cancer, including chemotherapy, immunotherapy, targeted therapy, and radiation therapy. The necessity for these therapies is driven by the global burden of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Applications are diverse, encompassing treatment regimens targeting specific genetic mutations, assisting in reducing tumor size pre-operatively, and enhancing post-operative recovery. End-use scope primarily includes hospitals, oncology centers, and academic and research institutions. Market growth is significantly influenced by advancements in precision medicine and a growing understanding of tumor genomics, leading to personalized treatment plans. Latest potential opportunities emerge from the increased approval rate of novel drugs and combinations, promising a shift towards more effective treatments with reduced side effects. Additionally, collaborations between pharmaceutical companies and research institutions are crucial to accelerating drug development and market entry. However, limitations such as high costs of therapy, prolonged approval processes, and the disparity in treatment accessibility across regions pose significant challenges. Complexities in clinical trials, patient recruitment, and regulatory challenges can also hinder market growth. The best areas for innovation currently lie in the development of liquid biopsies and companion diagnostics to better match patients with suitable therapies, as well as the exploration of new targets through genetic and molecular research. The market is dynamic, highly competitive, and characterized by rapid technological advancements, indicating a need for continuous R&D investment and strategic partnerships. Effective strategies to navigate this complex landscape include fostering innovation, maximizing patient access through pricing strategies, and maintaining agility to rapidly adapt to scientific and regulatory developments.

KEY MARKET STATISTICS
Base Year [2023] USD 25.04 billion
Estimated Year [2024] USD 27.12 billion
Forecast Year [2030] USD 44.03 billion
CAGR (%) 8.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in prevalence of lung cancer across the globe
    • Growing awareness regarding enhanced health care
    • Rising government initiatives for lung cancer treatment
  • Market Restraints
    • Huge availability of the generic drugs
    • Reduced life expectancy of patients undertaking lung cancer treatment
  • Market Opportunities
    • Increasing funding in the field of research and development of new treatment
    • Adoption of advanced therapy such as immunotherapy
  • Market Challenges
    • Risk of side effects of radiation and chemotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Therapeutics Market

A detailed market share analysis in the Lung Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Therapeutics Market

A strategic analysis of the Lung Cancer Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecules, market is studied across Biologics and Small Molecules.
  • Based on Disease, market is studied across NSCLC and SCLC.
  • Based on Cancer Type, market is studied across Lung Carcinoid Tumor, Non-small Cell Lung Cancer, and Small Cell Lung Cancer.
  • Based on Therapy, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy. The Immunotherapy is further studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab. The Radiation Therapy is further studied across External Beam, Internal Beam, and Systemic. The Targeted Therapy is further studied across Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, and Osimertinib.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Phramacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of lung cancer across the globe
      • 5.1.1.2. Growing awareness regarding enhanced health care
      • 5.1.1.3. Rising government initiatives for lung cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Huge availability of the generic drugs
      • 5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding in the field of research and development of new treatment
      • 5.1.3.2. Adoption of advanced therapy such as immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of side effects of radiation and chemotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lung Cancer Therapeutics Market, by Molecules

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Lung Cancer Therapeutics Market, by Disease

  • 7.1. Introduction
  • 7.2. NSCLC
  • 7.3. SCLC

8. Lung Cancer Therapeutics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Lung Carcinoid Tumor
  • 8.3. Non-small Cell Lung Cancer
  • 8.4. Small Cell Lung Cancer

9. Lung Cancer Therapeutics Market, by Therapy

  • 9.1. Introduction
  • 9.2. Chemotherapy
  • 9.3. Immunotherapy
    • 9.3.1. Atezolizumab
    • 9.3.2. Durvalumab
    • 9.3.3. Nivolumab
    • 9.3.4. Pembrolizumab
  • 9.4. Radiation Therapy
    • 9.4.1. External Beam
    • 9.4.2. Internal Beam
    • 9.4.3. Systemic
  • 9.5. Targeted Therapy
    • 9.5.1. Bevacizumab
    • 9.5.2. Dabrafenib/Trametinib
    • 9.5.3. Erlotinib Hydrochloride
    • 9.5.4. Osimertinib

10. Lung Cancer Therapeutics Market, by Distribution

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Phramacies
  • 10.4. Retail Pharmacies

11. Americas Lung Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Lung Cancer Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Lung Cancer Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Boehringer Ingelheim GmbH
  • 5. Bristol Myers Squibb Company
  • 6. Celgene Corporation
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. Genentech, Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Merck KGaA
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NSCLC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SCLC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LUNG CARCINOID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DABRAFENIB/TRAMETINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ERLOTINIB HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OSIMERTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHRAMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MI